中国药房2025，Vol.36Issue(22)：2833-2837,5.DOI:10.6039/j.issn.1001-0408.2025.22.14
HAIC-FOLFOX联合卡瑞利珠单抗用于不可切除肝细胞癌的临床观察
Clinical observation of HAIC-FOLFOX combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma
摘要
Abstract
OBJECTIVE To investigate the efficacy and safety of hepatic arterial infusion chemotherapy based on the oxaliplatin and fluorouracil drug combination(HAIC-FOLFOX)combined with camrelizumab in the treatment of unresectable hepatocellular carcinoma(HCC).METHODS The data of 222 unresectable HCC patients hospitalized at Liaoning Cancer Hospital&Institute from January 1,2021 to March 1,2023 were retrospectively collected.Based on treatment regimens,patients were divided into a control group(HAIC-FOLFOX+sorafenib,n=117)and an observation group(HAIC-FOLFOX+camrelizumab,n=105).Short-term efficacy indicators[objective remission rate(ORR)and disease control rate(DCR)]and long-term efficacy indicators[median overall survival(mOS)and median progression-free survival(mPFS)within one year]after 4 cycles of treatment,the levels of tumor markers(alpha fetoprotein,carcinoembryonic antigen,carbohydrate antigen 19-9),immune function indicators(CD3+,CD4+,and CD8+T-cell subsets)before treatment and after 4 cycles of treatment,as well as the occurrence of adverse reactions,were compared between two groups.RESULTS The ORR of the observation group was 55.24%,which was significantly higher than 35.90%of the control group(P＜0.05);while there was no statistically significant difference in DCR between the two groups(P＞0.05).The mOS and mPFS within 1 year of the observation group(15.33,10.83 months)were significantly longer than the control group(11.34,8.04 months)(P＜0.05).After 4 cycles of treatment,tumor marker levels of the two groups were significantly lower than before treatment,and the proportions of CD3+and CD4+T cells were significantly higher than before treatment(P＜0.05).Above indexes of the observation group were significantly better than the control group at the same time(P＜0.05).The proportions of patients in the observation group who developed grade 1-3 immune-related pneumonia and capillary proliferation were significantly higher than the control group(P＜0.05),while there were no statistically significant differences in the proportions of patients experiencing grade 1-3 adverse reactions such as fever,fatigue and rash between two groups(P＞0.05).CONCLUSIONS Compared with HAIC-FOLFOX combined with sorafenib,HAIC-FOLFOX combined with camrelizumab can significantly improve the ORR,prolong mOS and mPFS within 1 year,effectively reduce tumor marker levels,and improve certain immune function indicators in patients with unresectable HCC,but it increases the risk of immune-related adverse events.关键词
肝动脉灌注化疗/卡瑞利珠单抗/索拉非尼/不可切除肝细胞癌/有效性/安全性Key words
hepatic arterial infusion chemotherapy/camrelizumab/sorafenib/unresectable hepatocellular carcinoma/efficacy/safety分类
临床医学引用本文复制引用
祝平,卢西雅,田艳飞..HAIC-FOLFOX联合卡瑞利珠单抗用于不可切除肝细胞癌的临床观察[J].中国药房,2025,36(22):2833-2837,5.基金项目
辽宁省科学技术计划项目(No.2022-BS-061) （No.2022-BS-061）
